thumb
September 23, 2021

Biogen Issues First Progress Report of its Signature Healthy Climate, Healthy Lives™ Initiative

September 23, 2021  – In 2020, Biogen launched its signature Healthy Climate, Healthy Lives™ initiative, a groundbreaking $250 million, 20-year commitment to address the deeply interrelated issues of climate, health, and equity. Biogen is the first Fortune 500 company to commit to becoming fossil

thumb
September 21, 2021

Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

33 early and late-stage clinical programs across modalities and innovative discovery platforms Uniquely positioned to lead in Alzheimer’s disease with ADUHELM ® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in several areas of

thumb
September 20, 2021

FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

BYOOVIZ™ becomes the first ophthalmology biosimilar to gain FDA approval in the United States INCHEON, Korea and CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S.

thumb
September 17, 2021

CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate with a well-characterized efficacy and safety profile Data from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile Upon approval, VUMERITY

thumb
September 16, 2021

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced positive topline results from its

thumb
September 15, 2021

Biogen Announces Agenda for Virtual Investor Day R&D Day on September 21, 2021

CAMBRIDGE, Mass. – September 15, 2021 – Biogen Inc. (Nasdaq: BIIB) today announced the agenda for its Investor R&D Day. During this virtual event, Biogen’s management and scientific leaders will provide a comprehensive review of the Company’s robust and diversified neuroscience pipeline.

thumb
September 15, 2021

Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)

Clinical data available to date suggest there are remaining unmet needs in some spinal muscular atrophy (SMA) patients treated with Evrysdi 1 -3 The ASCEND study aims to evaluate whether treatment with a higher dose of nusinersen has the potential to improve clinical outcomes in these patients

thumb
September 1, 2021

Biogen to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Cambridge, MA.— Biogen Inc. (Nasdaq: BIIB) announced today that it will participate in a live Q&A at the Morgan Stanley 19th Annual Global Healthcare Conference. The webcast will be live on Thursday, September 9, at 9:30 a.m. ET. To access the live webcast, please visit Biogen’s Investors section

thumb
August 2, 2021

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

Results show that every six-week natalizumab IV administration provides a high level of efficacy in controlling MS disease activity in patients who switched from the approved every four-week dosing regimen Data from the first prospective, randomized, controlled study of an extended dosing schedule

thumb
July 29, 2021

Late-Breaking AAIC Presentation Explores Potential Clinical Effects of LECANEMAB (BAN2401)

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following  18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at  2021 Alzheimer’s Association International Conference (AAIC)   Eisai Co., Ltd.

thumb
July 29, 2021

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice ICARE AD-US is one of three programs to generate post-approval data on ADUHELM, including the re-dosing Phase 3b EMBARK study and the planned confirmatory Phase